
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Etoricoxib
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Infinite Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain
Details : Etoricoxib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Etoricoxib
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Infinite Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Recipient : Materno-Perinatal Hospital of the State of Mexico
Deal Size : Inapplicable
Deal Type : Inapplicable
Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide
Details : Nitazoxanide is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Coronavirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2020
Lead Product(s) : Nitazoxanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Recipient : Materno-Perinatal Hospital of the State of Mexico
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quadrivalent Recombinant Hemagglutinin Influenza Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : EPIC Research CRO | ILS Clinical Research | Q Square Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quadrivalent Recombinant Hemagglutinin Influenza Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 09, 2018
Lead Product(s) : Quadrivalent Recombinant Hemagglutinin Influenza Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : EPIC Research CRO | ILS Clinical Research | Q Square Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
